JP2022546577A5 - - Google Patents
Info
- Publication number
- JP2022546577A5 JP2022546577A5 JP2022514522A JP2022514522A JP2022546577A5 JP 2022546577 A5 JP2022546577 A5 JP 2022546577A5 JP 2022514522 A JP2022514522 A JP 2022514522A JP 2022514522 A JP2022514522 A JP 2022514522A JP 2022546577 A5 JP2022546577 A5 JP 2022546577A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- nucleic acid
- region
- amino acid
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962896190P | 2019-09-05 | 2019-09-05 | |
| US62/896,190 | 2019-09-05 | ||
| US201962896990P | 2019-09-06 | 2019-09-06 | |
| US62/896,990 | 2019-09-06 | ||
| US201962910341P | 2019-10-03 | 2019-10-03 | |
| US62/910,341 | 2019-10-03 | ||
| US201962943069P | 2019-12-03 | 2019-12-03 | |
| US62/943,069 | 2019-12-03 | ||
| US202063030145P | 2020-05-26 | 2020-05-26 | |
| US63/030,145 | 2020-05-26 | ||
| PCT/US2020/049538 WO2021046445A1 (en) | 2019-09-05 | 2020-09-04 | Dimeric antigen receptors (dar) that bind bcma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022546577A JP2022546577A (ja) | 2022-11-04 |
| JP2022546577A5 true JP2022546577A5 (enExample) | 2023-09-11 |
Family
ID=74852154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022514522A Pending JP2022546577A (ja) | 2019-09-05 | 2020-09-04 | Ｂｃｍａと結合する二量体抗原受容体（ｄａｒ） |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220251168A1 (enExample) |
| EP (1) | EP4025227A4 (enExample) |
| JP (1) | JP2022546577A (enExample) |
| KR (1) | KR20220057598A (enExample) |
| CN (1) | CN114650829A (enExample) |
| AU (1) | AU2020341712A1 (enExample) |
| CA (1) | CA3149867A1 (enExample) |
| IL (1) | IL291076A (enExample) |
| MX (1) | MX2022002723A (enExample) |
| WO (1) | WO2021046445A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210133261A (ko) * | 2019-02-26 | 2021-11-05 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Bcma에 결합하는 항원 결합 단백질 |
| EP4139345A1 (en) | 2020-04-24 | 2023-03-01 | Sorrento Therapeutics, Inc. | Memory dimeric antigen receptors |
| EP4326292A4 (en) * | 2021-04-23 | 2025-03-26 | Vivasor, Inc. | Dimeric antigen receptors (dars) that bind gd2 |
| IL311141A (en) * | 2021-09-06 | 2024-04-01 | Genmab As | Antibodies capable of binding to CD27, their variants and uses thereof |
| CN117986387A (zh) * | 2023-05-31 | 2024-05-07 | 四川大学华西医院 | 一种新型小型化car设计及制备方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170051037A1 (en) * | 2014-05-02 | 2017-02-23 | Cellectis | Cs1 specific multi-chain chimeric antigen receptor |
| EP3842448A1 (en) * | 2015-05-15 | 2021-06-30 | City of Hope | Chimeric antigen receptor compositions |
| US11173179B2 (en) * | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
| MX2018004721A (es) * | 2015-10-23 | 2018-07-06 | Eureka Therapeutics Inc | Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas. |
| AU2018290272A1 (en) * | 2017-06-21 | 2020-01-30 | Gsbio, Llc | Heterodimeric bispecific antibodies |
| SG11202003501XA (en) * | 2017-11-01 | 2020-05-28 | Juno Therapeutics Inc | Antibodies and chimeric antigen receptors specific for b-cell maturation antigen |
| AU2019231315A1 (en) * | 2018-03-09 | 2020-09-17 | Vivasor, Inc. | Dimeric antigen receptors (DAR) |
| KR20210133261A (ko) * | 2019-02-26 | 2021-11-05 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Bcma에 결합하는 항원 결합 단백질 |
-
2020
- 2020-09-04 JP JP2022514522A patent/JP2022546577A/ja active Pending
- 2020-09-04 KR KR1020227011203A patent/KR20220057598A/ko not_active Ceased
- 2020-09-04 EP EP20861409.9A patent/EP4025227A4/en not_active Withdrawn
- 2020-09-04 CA CA3149867A patent/CA3149867A1/en active Pending
- 2020-09-04 WO PCT/US2020/049538 patent/WO2021046445A1/en not_active Ceased
- 2020-09-04 MX MX2022002723A patent/MX2022002723A/es unknown
- 2020-09-04 CN CN202080076523.8A patent/CN114650829A/zh active Pending
- 2020-09-04 AU AU2020341712A patent/AU2020341712A1/en not_active Abandoned
-
2022
- 2022-03-02 IL IL291076A patent/IL291076A/en unknown
- 2022-03-03 US US17/686,261 patent/US20220251168A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022546577A5 (enExample) | ||
| Azuma | Co-signal molecules in T-cell activation: historical overview and perspective | |
| US11390658B2 (en) | Anti-CD7 chimeric antigen receptor and method of use thereof | |
| Ranheim et al. | Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. | |
| JP2020517295A5 (enExample) | ||
| US5686281A (en) | Chimeric receptor molecules for delivery of co-stimulatory signals | |
| JP2020511529A5 (enExample) | ||
| JP2021500881A5 (enExample) | ||
| JP2020533958A5 (enExample) | ||
| JP2024507996A5 (enExample) | ||
| US11760806B2 (en) | CD-38 directed chimeric antigen receptor constructs | |
| JP2022534680A5 (enExample) | ||
| JP2018535701A5 (enExample) | ||
| JP2018529376A5 (enExample) | ||
| JP2017524367A5 (enExample) | ||
| JP2024527557A5 (enExample) | ||
| RU2017109966A (ru) | Условно активные химерные антигенные рецепторы для модифицированных т-клеток | |
| JP7723420B2 (ja) | Ｂ細胞標的化並列ＣＡＲ（ｐＣＡＲ）治療的薬剤 | |
| JP2024534847A5 (enExample) | ||
| JP2022530773A5 (enExample) | ||
| WO2022036224A1 (en) | Chimeric antigen receptor t cells for treating autoimmunity | |
| US20240261330A1 (en) | CD19-Directed Chimeric Antigen Receptor Constructs | |
| US20240173411A1 (en) | Methods for treating cd83-expressing cancer | |
| JP2023516595A5 (enExample) | ||
| Teschner | Use of TCR antibody fusion proteins as bispecific agents for NK and T cell-mediated immunotherapy |